Tetradecylthioacetic acid is a laboratory-made fatty acid, sold as a supplement and studied for its effects on blood fats. Its most credible benefit is short-term blood-fat improvement in selected clinical settings. Weight loss, better glucose control, fewer heart attacks, and longer life are not established. Short exposures were generally tolerated but say little about long-term harms; most research comes from one closely connected group with disclosed commercial interests. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting lipid profile | LDL below 100 mg/dL (2.6 mmol/L); triglycerides below 100 mg/dL (1.1 mmol/L); HDL above 50 mg/dL (1.3 mmol/L) | Measure intended response |
| Fasting glucose | 75–90 mg/dL (4.2–5.0 mmol/L) | Detect metabolic change |
| Liver enzymes and bilirubin | ALT and AST about 10–25 U/L; bilirubin 0.3–1.0 mg/dL (5–17 µmol/L) | Detect possible liver injury |
| Creatinine and estimated filtration rate | Estimated filtration rate above 90 mL/min/1.73 m²; creatinine about 0.7–1.1 mg/dL, varying with muscle mass | Detect kidney change |
| Sodium, potassium, magnesium | Sodium 138–142 mmol/L; potassium 4.0–4.8 mmol/L; serum magnesium 2.0–2.4 mg/dL (0.82–0.99 mmol/L) | Evaluate cramps or weakness |
| Complete blood count | Hemoglobin 13.5–15.5 g/dL (men) or 12.5–14.5 g/dL (women); platelets 175–250 ×10⁹/L | Identify blood-cell changes |
| Blood pressure and resting pulse | Below 120/80 mmHg; resting pulse 55–70 beats per minute | Detect circulation changes |
| Plasma fatty-acid profile, if available | Omega-3 index 8–12% when measured | Characterize omega-3 shifts |
Cadence: Baseline; day 14 and day 28 (mirrors the registered diabetes study); two to four weeks after cessation (extrapolation); earlier if symptoms occur. No target ranges specific to tetradecylthioacetic acid are validated; changes from baseline provide context.